ascorbic-acid and Cough

Topics: Acetaminophen; Aerosols; Aminophylline; Analgesics; Analgesics, Non-Narcotic; Animals; Antimony; Antipyretics; Antitussive Agents; Ascorbic Acid; Bronchodilator Agents; Caffeine; Codeine; Cough; Dogs; Electric Stimulation; Electrophysiology; Expectorants; Histamine H1 Antagonists; Hypnotics and Sedatives; Ion Exchange Resins; Noscapine; Parasympatholytics; Pharmacology; Phenothiazines; Promethazine; Reflex; Research; Sodium Salicylate; Sympathomimetics

There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.. To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.. This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020.. Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.. The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements.. A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups.. In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care.. ClinicalTrials.gov Identifier: NCT04342728.

Topics: Adult; Ambulatory Care; Antioxidants; Ascorbic Acid; Cough; COVID-19; COVID-19 Drug Treatment; Dietary Supplements; Dyspnea; Fatigue; Female; Fever; Gluconates; Humans; Male; Middle Aged; SARS-CoV-2; Severity of Illness Index; Standard of Care; Trace Elements; Treatment Outcome; Zinc

This pilot study investigates the efficacy of a probiotic consortium (Lab4) in combination with vitamin C on the prevention of respiratory tract infections in children attending preschool facilities.. In a double-blind, randomised, placebo-controlled pilot study with children aged 3-6 years, 57 received 1.25 × 10(10) colony-forming units of Lactobacillus acidophilus CUL21 (NCIMB 30156), Lactobacillus acidophilus CUL60 (NCIMB 30157), Bifidobacterium bifidum CUL20 (NCIMB 30153) and Bifidobacterium animalis subsp. lactis CUL34 (NCIMB 30172) plus 50 mg vitamin C or a placebo daily for 6 months.. Significant reductions in the incidence rate of upper respiratory tract infection (URTI; 33%, P=0.002), the number of days with URTI symptoms (mean difference: -21.0, 95% confidence interval (CI):-35.9, -6.0, P=0.006) and the incidence rate of absence from preschool (30%, P=0.007) were observed in the active group compared with the placebo. The number of days of use of antibiotics, painkillers, cough medicine or nasal sprays was lower in the active group and reached significance for use of cough medicine (mean difference: -6.6, 95% CI: -12.9, -0.3, P=0.040). No significant differences were observed in the incidence rate ratio or duration of lower respiratory tract infection or in the levels of plasma cytokines, salivary immunoglobulin A or urinary metabolites.. Supplementation with a probiotic/vitamin C combination may be beneficial in the prevention and management of URTIs.

Topics: Absenteeism; Antitussive Agents; Ascorbic Acid; Bifidobacterium; Child, Preschool; Cough; Double-Blind Method; Female; Humans; Incidence; Lactobacillus acidophilus; Male; Pilot Projects; Probiotics; Respiratory Tract Infections; Schools; Vitamins

A randomized controlled trial of the effect of 1 g ascorbic acid per day in the prevention of the common cold was conducted on 688 adult women. There is evidence of a small reduction by vitamin C in the mean number of chest colds, but no evidence of any effect on simple colds. The existence of a subgroup of vulnerable women in the community who benefit from vitamin C was considered but further examination of the data gives no support to this conclusion.

Topics: Adult; Ascorbic Acid; Clinical Trials as Topic; Common Cold; Cough; Female; Humans; Placebos; Time Factors

Topics: Adolescent; Age Factors; Arizona; Ascorbic Acid; Child; Clinical Trials as Topic; Cough; Drug Evaluation; Female; Humans; Male; Placebos; Residential Facilities; Respiratory Tract Infections; Seasons; Sex Factors; Tablets

The Coronavirus disease 2019 (COVID-19) pandemic has had a devastating impact on health systems, food supplies, and population health. This is the first study to examine the association between zinc and vitamin C intakes and the risk of disease severity and symptoms among COVID-19 patients.. This cross-sectional study included 250 recovered COVID-19 patients aged 18-65 years from June to September 2021. Data on demographics, anthropometrics, medical history, and disease severity and symptoms were collected. Dietary intake was evaluated using a web-based, 168-item food frequency questionnaire (FFQ). The severity of the disease was determined using the most recent version of the NIH COVID-19 Treatment Guidelines. Using multivariable binary logistic regression, the association between zinc and vitamin C intakes and the risk of disease severity and symptoms in COVID-19 patients was evaluated.. The mean age of participants in this study was 44.1 ± 12.1, 52.4% of them were female, and 46% had a severe form of the disease. Participants with higher zinc intakes had lower levels of inflammatory cytokines, such as C-reactive protein (CRP) (13.6 vs. 25.8 mg/l) and erythrocyte sedimentation rate (ESR) (15.9 vs. 29.3). In a fully adjusted model, a higher zinc intake was also associated with a lower risk of severe disease (OR: 0.43; 95% CI: 0.21, 0.90, P-trend = 0.03). Similarly, participants with higher vitamin C intakes had lower CRP (10.3 vs. 31.5 mg/l) and ESR serum concentrations (15.6 Vs. 35.6) and lower odds of severe disease after controlling for potential covariates (OR: 0.31; 95% CI: 0.14, 0.65, P-trend = <0.01). Furthermore, an inverse association was found between dietary zinc intake and COVID-19 symptoms, such as dyspnea, cough, weakness, nausea and vomiting, and sore throat. Higher vitamin C intake was associated with a lower risk of dyspnea, cough, fever, chills, weakness, myalgia, nausea and vomiting, and sore throat.. In the current study, higher zinc and vitamin C intakes were associated with decreased odds of developing severe COVID-19 and its common symptoms.

Topics: Ascorbic Acid; Cough; COVID-19; COVID-19 Drug Treatment; Cross-Sectional Studies; Eating; Female; Humans; Logistic Models; Male; Pharyngitis; Vitamins; Zinc

Topics: Abdominal Pain; Anemia; Antioxidants; Ascorbic Acid; Child, Preschool; Cough; Cytochrome-B(5) Reductase; Diagnosis, Differential; Emergency Service, Hospital; Glucosephosphate Dehydrogenase Deficiency; Headache; Humans; Hypoxia; Intensive Care Units; Jaundice; Male; Methemoglobinemia; Methylene Blue; Morocco; Oxygen Inhalation Therapy; United States; Vicia faba

Inhalation of high concentration of oxygen produces oxidative stress in men and experimental animals. Our previous experiments showed that the cough reflex is suppressed in guinea pigs after exposure to 100% O(2) for 60 hours. The aim of this study was to determine the effects of dietary antioxidant supplementation with vitamins C and E on hyperoxia-induced oxidative stress in airway and lung tissues directed on cough reflex. The experimental group (T-H, n=8) was pretreated with vitamins C (500 mg/kg) and E (300 mg/kg) for 4 weeks and subsequently exposed to 100% O(2) for 60 hours. Hyperoxic group (H, n=8) received saline instead of antioxidants and then inhaled 100% O(2) for 60 hours. Cough was induced by inhalation of citric acid aerosol in gradually increased concentration (0.05-1.6 M) at the end of antioxidant therapy and then at the end of exposure to 100% O(2). Cough was also induced by mechanical stimulation of laryngopharyngeal (LPh) and tracheobronchial (TBr) region in anaesthetized animals just 1 hour after the end of oxygen exposure. Our results showed a tendency to a decrease in citric acid-induced cough in hyperoxic animals and an increase in animals with antioxidant therapy after hyperoxia. Antioxidant therapy significantly unblocked hyperoxia-induced down-regulation of cough (P=0.004). Significant changes also were obtained from mechanically-induced TBr cough [2.5(1-4) vs. 1.0(1-2); P<0.01] between the experimental and hyperoxic (control) animals. In conclusion, our results indicate a protective effect of antioxidant supplementation on oxidant-mediated cough depression.

Topics: Animals; Antioxidants; Ascorbic Acid; Citric Acid; Cough; Guinea Pigs; Lung; Male; Oxidative Stress; Oxygen Inhalation Therapy; Physical Stimulation; Reflex; Vitamin E; Vitamins

We aimed to investigate whether dietary vitamin C intake, an important antioxidant, is inversely related to self-reported respiratory symptoms in young adults of a community. A random sample of 4300 subjects, aged 20-44 years, living in Bergen, Norway, received a postal questionnaire on respiratory symptoms; 80% responded. Vitamin C intake (mg per week) was estimated from a food-frequency questionnaire asking how often the subject, during the last year, had consumed units of orange juice, oranges, potatoes, carrots and tomatoes. Significant differences in the intake of vitamin C were observed across smoking categories with current smokers having the lowest intake, while there was no variation by gender, age or occupational dust exposure. Dietary vitamin C intake was in univariate analyses inversely related to "morning cough", "chronic cough", "wheeze" and "wheeze ever". After adjusting for gender, age, body mass index, "occupational exposure" pack-years as well as having and stratified on smoking habits in multiple logistic regression analyses, the relationship between dietary vitamin C intake and "cough" and "wheeze" tended to be associated to smoking. The odds ratio (OR) for "morning cough" was 0.68 (95% CI: 0.35-0.95), "chronic cough" OR 0.69 (95% CI: 0.47-1.04) and "wheeze ever" OR 0.75 (95% CI: 0.56-1.01) in current-smokers with dietary vitamin C intake in the upper (> or =395 mg/ week) vs. the lower (<209 mg/week) tertile. The OR for "wheeze" was 0.56 (95% CI: 0.35-0.88) in ex-smokers. The magnitude ofthese effects remained after excluding subjects with supplementary vitamin C intake (n=199) from the statistical analyses. Among young Norwegian adults, having a low prevalence of asthma and high prevalences of smoking-related respiratory symptoms, dietary vitamin C intake may act as an antioxidant and thereby reduce cough and wheeze in smokers having high oxidant stress.

Topics: Adult; Antioxidants; Ascorbic Acid; Cough; Cross-Sectional Studies; Diet; Female; Humans; Male; Norway; Odds Ratio; Regression Analysis; Respiratory Sounds; Smoking

A study was undertaken to investigate the relationships between the intake of the antioxidant (pro)-vitamins C, E and beta-carotene and the presence of respiratory symptoms and lung function.. Complete data were collected in a cross sectional study in a random sample of the Dutch population on 6555 adults during 1994 and 1995. Antioxidant intake was assessed by a semi-quantitative food frequency questionnaire and respiratory symptoms (cough, phlegm, productive cough, wheeze, shortness of breath) were assessed by a self-administered questionnaire. Prevalence odds ratios for symptoms were calculated using logistic regression analysis. Linear regression analysis was used for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). The results are presented as a comparison between the 90th and 10th percentiles of antioxidant intake.. Vitamin C intake was not associated with most symptoms but was inversely related with cough. Subjects with a high intake of vitamin C had a 53 ml (95% CI 23 to 83) higher FEV1 and 79 ml (95% CI 42 to 116) higher FVC than those with a low vitamin C intake. Vitamin E intake showed no association with most symptoms and lung function, but had a positive association with productive cough. The intake of beta-carotene was not associated with most symptoms but had a positive association with wheeze. However, subjects with a high intake of beta-carotene had a 60 ml (95% CI 31 to 89) higher FEV1 and 75 ml (95% CI 40 to 110) higher FVC than those with a low intake of beta-carotene.. The results of this study suggest that a high intake of vitamin C or beta-carotene is protective for FEV1 and FVC compared with a low intake, but not for respiratory symptoms.

Topics: Adult; Antioxidants; Ascorbic Acid; beta Carotene; Cough; Cross-Sectional Studies; Data Collection; Humans; Lung; Middle Aged; Prevalence; Regression Analysis; Respiration Disorders; Respiratory Sounds; Vitamin E; Vitamins

We investigated the acute effect of ascorbic acid on histamine bronchial responsiveness (PC 20: concentration causing a 20% fall in FEV1) in 9 hospital staff members with upper respiratory tract infection (URI) and cough. Subjects were examined within 5 days from the start of illness and 6 weeks after. On day 1, the reproducibility of PC20 was assessed by 2 consecutive inhalation challenges 1 h apart; the two values were closely related (r = 0.96, p less than 0.001). Five subjects had bronchial hyperresponsiveness (PC20 less than 8 mg/ml histamine). On the following day, PC20 was measured before and 1 h after oral intake of 2 g ascorbic acid. Vitamin C produced a significant increase in average PC20 (p less than 0.01) from 7.8 +/- (SE) 1.2 to 25.1 +/- (SE) 1.2 mg/ml. None had airway hyperresponsiveness after treatment. Six weeks after the onset of URI, bronchial responsiveness was normal in all the subjects but one. The mean PC20 was 15.5 +/- (SE) 1.25 mg/ml, significantly higher than during URI (p less than 0.05); after ascorbic acid it increased nonsignificantly to 25.7 +/- (SE) 1.35 mg/ml. Our results indicate that vitamin C inhibits the transient increase in bronchial responsiveness occurring in otherwise normal subjects during URI.

Topics: Adult; Ascorbic Acid; Bronchi; Bronchial Provocation Tests; Cough; Female; Histamine; Humans; Male; Middle Aged; Respiratory Tract Infections

Joshandah, polypharmaceutical herbal preparations, are used in the form of a sweetened decoction for the treatment of common cold, catarrh, cough and associated fevers in Unani (Greco-Arab) medicine. The rationale of their therapeutic efficacy is discussed in the light of reported chemico-pharmacological properties of the ingredients.

Topics: Ascorbic Acid; Common Cold; Cough; Fever; Humans; Phytotherapy; Plants, Medicinal

Topics: Adenoviridae; Adenoviridae Infections; Antiviral Agents; Ascorbic Acid; Common Cold; Cough; Culture Techniques; Humans; Infections; Orthomyxoviridae; Orthomyxoviridae Infections; Picornaviridae; Respiratory Tract Infections; Virus Diseases

Topics: Aerosols; Ascorbic Acid; Cough; Vitamins; Whooping Cough